April 1, 2019
Takeda Pharmaceutical said on March 29 that it has filed an application in Japan, seeking to expand the label of its CD30-targeting antibody-drug conjugate (ADC) Adcetris (brentuximab vedotin) into peripheral T-cell lymphoma (PTCL) and pediatric use in its current indications...read more